Work from our laboratory demonstrated that in neuroblastoma and myeloid leukemia, inhibition or deletion of TRPM2 significantly reduces proliferation and increases sensitivity to doxorubicin3,21,25. Here, TRPM2 is linked to myeloid leukemia.